Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?
Speer
C P
CP
Department of Pediatrics, University Children 's Hospital, Wuerburg, Germany.
Robertson
B
B
Halliday
H L
HL
D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D010743:Phospholipids; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000493:pharmacokinetics; D011663:Pulmonary Surfactants / Q000009:adverse effects* / Q000493:pharmacokinetics; D016032:Randomized Controlled Trials as Topic; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D012306:Risk; D018805:Sepsis / Q000453:epidemiology*
D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols; D010743:Phospholipids; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; C068291:poractant alfa